Background: Malignant melanoma is the most lethal form of cutaneous tumor and has a high metastatic rate and motility capacity. Owing to the poor prognosis, it is urgent to seek an effective therapeutic regimen. Human mesenchymal stem cells (MSCs) can home to tumor cells and have been shown to play important roles in both promoting and inhibiting tumor development. Fetal dermal MSCs (FDMSCs), derived from fetal skin are a novel source of MSCs. Nevertheless, the antitumor capacity of FDMSCs on malignant melanoma is not clearly understood. Materials and methods: FDMSCs were extracted from the dorsal skin of fetal tissues. A375 melanoma cells lines were obtained from American Type Culture Collection. The effects of conditioned media from FDMSCs (CM-FDMSC) on A375 melanoma cells were tested in vivo using tumor formation assay and in vitro using cell viability, 5-ethynyl-2ʹ-deoxyuridine incorporation, flow cytometry, TdT-mediated dUTP Nick-End Labeling (TUNEL), wound healing, transwell invasion, and Western blotting. Results: CM-FDMSC inhibited A375 tumor formation in vivo. In vitro, CM-FDMSC inhibited the tumor-related activities of A375 melanoma cells, as evidenced reductions in viability, migration, and invasion. CM-FDMSC-treated A375 cells showed decreased phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and extracellular signal-regulated kinase (ERK) phosphorylation, and up-regulation of Bcl-2-Associated X (BAX) and downregulation of B-cell lymphoma-2 (BCL-2) expression. Conclusion: CM-FDMSC can inhibit the tumor-forming behaviors of A375 melanoma cells and inhibit PI3K/AKT and mitogen-activated protein kinase signaling to shift their BCL-2/ BAX ratio toward a proapoptotic state. Identification of the bioactive components in CM-FDMSC will be important for translating these findings into novel therapies for malignant melanoma.
Introduction
Malignant melanoma is one of the most aggressive skin tumors derived from malfunctioning of normal melanocytes. The incidence of melanomas continues to increase at a high rate, particularly in western populations. 1, 2 Although melanoma therapies. 5, 6 Therefore, it is urgent to develop alternative and innovative therapies to improve clinical outcomes. Mesenchymal stem cells (MSCs) exist in various tissues, including bone marrow, adipose tissue, synovial membrane, periodontal ligament, and skin. [7] [8] [9] [10] MSCs are pluripotent progenitor cells and have shown potential in tissue engineering and regenerative medicine. 11 Previous studies suggested that MSCs might become a promising treatment strategy for neurological dysfunctions, diabetic, cardiomyopathy, glaucoma, and urological diseases. [12] [13] [14] [15] Importantly, MSCs can effectively inhibit the development of some types of tumors. [16] [17] [18] [19] Fetal dermal MSCs (FDMSCs) can be isolated from aborted fetal skin and have the ability to differentiate into multiple cell types, although their full characteristics are still under investigation. Our previous study showed that paracrine factors secreted by FDMSCs could inhibit keloid growth. 20 Phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway regulates most hallmarks of cancer, including cell survival, metabolism, motility, invasion, and genomic instability. 21 Activation of the PI3K pathway can promote tumor development by enhancing cell survival. Mitogen-activated protein kinase (MAPK) signal pathway plays an important role in many biological functions such as cell proliferation, adhesion, survival, and differentiation. It also participates in tumorigenesis and regulates the apoptotic process. MAPK pathway is activated in most melanomas because of the oncogenic serinethreonine protein kinase B-RAF (BRAF) mutations. Inhibiting MAPK pathway shows therapeutic benefit in melanoma treatment. [22] [23] [24] Thus, we hypothesized that the antitumor effects of FDMSCs were mediated by paracrine manner through PI3K/AKT and MAPK signaling pathways. Our studies revealed that CM-FDMSC inhibits A375 cell behaviors associated with tumor formation in vivo and in vitro. Our data supports a model wherein biologically active factors present in CM-FDMSC inhibit PI3K/AKT and MAPK signaling to promote apoptosis of A375 melanoma cells and suggests that FDMSC-derived paracrine factors could lead to novel therapeutic approaches for melanoma.
Methods and materials
Cell culture and preparation of conditioned media from FDMSCs 
Wound healing
For the wound healing assay, A375 melanoma cells were cultured in 60-mm plates until confluent, and then each monolayer was scratched with a 200 μL pipette tip to create a mechanical wound. The cells were cultured in different concentrations of CM-FDMSC for 48 hrs. Brightfield images were captured using an inverted microscope (Nikon, Japan) equipped with Camera and NIS-Elements software (Nikon, Japan).
Transwell invasion assay
The upper chamber of transwells (8 µm pore size polycarbonate membrane, Corning Costar, USA) was coated with 50 µL Matrigel matrix (BD, Franklin Lakes, NJ, USA, 1:3 diluted with serum-free DMEM medium). A375 melanoma cells were suspended (5×10 5 cells/mL) in different concentrations of CM-FDMSC or control medium, with 200 µL of the suspension was added into the upper transwell chamber and complete medium (800 µL) was added to the lower chamber. After incubation for 14 hrs, cells were fixed with 4% paraformaldehyde, stained with crystal violet (Beyotime; Shanghai, China), and cells on the lower surface of the membrane were counted using a microscope at 200× magnification in different areas in three independent repeated experiments.
Western blotting assay
Western blotting was performed following standard protocols. Briefly, after CM-FDMSC treatment, A375 melanoma cells were lysed with protease and phosphatase inhibitors and total proteins were extracted using RIPA lysis buffer on ice. Proteins were boiled for 3 mins and separated on a 12% polyacrylamide gel. Protein expression and phosphorylation were monitored with specific antibodies and chemiluminescent horseradish peroxidase Substrate (Millipore, USA), and imaged with film (Carestream, China). The images were quantified using 
Statistical analysis
For each assay, data for each treatment condition were averaged from three or more independent experiments, and the mean and SD calculated. Student's t-test was used for single comparisons. Time-course and multigroup analyses were performed using ANOVA. Tukey's post hoc test was used to detect differences between groups. P-value <0.05 was considered as statistically significant. GraphPad Prism 5 and SPSS 11.5 software were used for graphs and statistical analysis.
Results

CM-FDMSC inhibits melanoma tumor growth in nude mouse
To detect the antitumor activity of CM-FDMSC, we used a melanoma mouse model, in which A375 melanoma cells were injected subcutaneously. The tumor volumes were continuously observed every 3 days and on day 17, tumors were harvested and weighted, respectively ( Figure 1A and B). Tumor volumes and weight showed a dose-dependent decrease in CM-treated groups compared to control ( Figure 1C and D) . H&E and IHC staining of tumors showed histological differences among groups ( Figures 1E and 2A-C) . Qualitatively, in the control group, there were more tumor cells (containing more blue nuclei) with higher proliferative rate (containing more Ki67 positive cells), less connective tissues (lower collagen IV and fibronectin expression), and the tumor capsules were thin (indicated by the black arrows). With increasing concentrations of CM-FDMSC, the quantity and density of tumor cells decreased, as well as Ki67-positive cells. In addition, the tumor connective tissues became abundant, as shown in the IHC of collagen IV and fibronectin, and the thickness of tumor capsules increased. In 2× CM, a distinct tissue boundary formed (indicated by the black arrows). Collectively, these results demonstrated that CM-FDMSC inhibited tumor growth by A375 cells.
CM-FDMSC inhibits the viability of A375 melanoma cells
We measured the viability and proliferation of A375 melanoma cells in vitro using CCK-8 kit and EdU incorporation, respectively, to examine if CM-FDMSC can affect tumor cells vitro. There was a dose-dependent decrease in A375 melanoma cell viability with increasing concentrations of CM-FDMSC, as evidenced by changes in A 450 absorbance by the formazan dye ( Figure 3A ). Despite the reduction in cell viability and the visible reduction in the density of Hoechst-positive nuclei in CM-FDMSC-treated A375 melanoma cells ( Figure 3B ), there were no significant differences in the percent of cells incorporating EdU across treatment groups ( Figure 3C ). The results demonstrated that the inhibitory effect of CM-FDMSC was attributable to effects on cell viability rather than cell proliferation. 
CM-FDMSC induces the apoptosis of A375 melanoma cells
CM-FDMSC inhibits migration and invasion of A375 melanoma cells
Another aspect of tumorigenicity is the ability of cells to migrate and metastasize. Therefore, monolayer wound healing assays were performed to examine whether CM-FDMSC could affect the migration capacity of A375 melanoma cells ( Figure 6A ). After 48 hrs of CM-FDMSC treatment, A375 melanoma cell migration was markedly reduced in a dose-dependent manner ( Figure 6A and B). We next examined the effect of CM-FDMSC on the invasive capabilities of A375 melanoma cells using transwell invasion assays ( Figure 7A ). We found that pretreatment with CM-FDMSC significantly inhibited the invasive capacity of the A375 melanoma cells in a dosedependent manner as evidenced by the reduction in the number of cells present on the lower surface of the membranes compared to controls ( Figure 7B ). Taken together, our results suggested that CM-FDMSC inhibited both the migration and invasion capacity of A375 melanoma cells.
The PI3K/AKT pathway, MAPK pathway, and mitochondria-mediated internal apoptosis pathway are regulated in A375 melanoma cells
The PI3K/AKT signaling is considered an important pathway in tumorigenesis, and the MAPK pathway is activated in most melanomas. To further find the underlying mechanism of apoptosis-promoting effect and determine whether the antitumor effect of CM-FDMSC is associated with altered PI3K/ AKT and MAPK signaling, the expression of BAX, BCL-2, PI3K, AKT, and ERK and the phosphorylation of PI3K, AKT, ERK ( Figure 8A -C) were observed by Western blot. CM-FDMSC induced significant increases in expression of the proapoptotic protein BAX and significant decreases in expression of the anti-apoptotic protein BCL-2 ( Figure 8D and E), consistent with activation of the mitochondriamediated internal apoptosis pathway. It is well known that the ratio of BCL-2/BAX is a significant indication of cell apoptosis. 25, 26 Thus, the dose-dependent decrease in the BCL-2/BAX ratio and increase in both TUNEL and Annexin staining of A375 melanoma cells with increasing concentrations of CM-FDMSC are consistent with induction of apoptosis. In addition, the phosphorylation of PI3K, AKT, and ERK decreased with increasing concentrations of CM-FDMSC ( Figure 8F-H) , although total PI3K, AKT, and ERK levels were not significantly different between groups. Thus, the decrease in the p-PI3K/PI3K, p-AKT/AKT, and p-ERK/ ERK ratios with increasing concentrations of CM-FDMSC indicates inhibition of PI3K/AKT and MAPK signaling.
Discussion
Stem cell therapy has emerged as a promising strategy to prolong survival time and improve the treatment efficiency of patients with cancer compared to some traditional therapies. Previously, our team demonstrated that FDMSCs could accelerate apoptosis of keloid fibroblasts through regulating BCL-2 and BAX expression levels, providing a novel treatment therapy for keloid. 20 Furthermore, another report revealed that human fetal bone marrowderived MSCs could inhibit cell proliferation on hepatocellular carcinoma cells through reduced activation of insulin-like growth factor (IGF)-1R/PI3K/AKT signaling. 19 Interestingly, skin MSCs were eventually shown to be derived from melanocyte precursors. 27 Thus, we hypothesized that human FDMSCs would also exert antitumor effects on A375 melanoma cells, because of their lineage relationships with adult MSCs. Our previous studies confirmed that FDMSCs could accelerate the apoptosis of keloid fibroblasts through in a paracrine way, without direct cell contact. 18, 28 The results of the current study support our hypothesis and show that CM-FDMSC inhibits the bioactivity of A375 melanoma cells and has antitumor effects in vivo and in vitro.
CM-FDMSC contains factors that reduce various aspects of tumorigenicity of A375 melanoma cells. We confirmed that CM-FDMSC inhibits A375 melanoma cell expansion by inducing apoptosis of A375 melanoma cells, rather than inhibiting the proliferation, consistent with previous reports. 29 In addition, migration and invasion abilities of A375 melanoma cells were suppressed by CM-FDMSC in both the monolayer wound healing and transwell invasion assays and again were consistent with previous reports. 30 In contrast, conditioned media from bone marrow
MSCs significantly promoted the progression of head and neck cancer progression by enhancing cell proliferation and migration, and activation of the PI3K/AKT/mTOR signaling pathway. 31 Thus, the antitumoror pro-tumor effects of
MSCs derived factors in CM-FDMSC are likely to depend on many factors, such as the cellular origin of the MSCs, the dose of MSC exposure, the tumor cell characteristics, and the specific microenvironment. FDMSCs can express and secrete a set of biologically functional chemokines and tumor-suppressing agents, and a large body of studies focused on the specific components in CM-FDMSC that actually active in tumor inhibition. The candidate molecules are interferon-beta, tumor necrosis factor alpha, TGF-β1, and other immunomodulatory factors altering the tumor microenvironment and immune state. [32] [33] [34] Studies also identified that Dickkopf-1 (DKK-1) secreted by MSCs can inhibit cancer cell growth and proliferation by negatively regulating Wingless/Integrated (WNT) signaling. 35, 36 In a recent report, the results showed that the anti-proliferative factor in human fetal MSCs to inhibit liver cancer growth may be a direct effect of proteolysis of IGF-binding protein-3. by a combination effect of different molecular targeting different pathways. The precise mode of these candidate molecules exerting the inhibitor effect will require further investigations.
In our study, we also investigated the mechanism of CM-FDMSC-induced apoptosis of A375 melanoma cells at the protein level. BAX and BCL-2 are important markers for the mitochondria-mediate apoptotic pathway. Meanwhile, BAX and BCL-2 are downstream molecules of PI3K/AKT signaling pathway. In A375 melanoma cells, expression of BAX was up-regulated and expression of BCL-2 was downregulated after treatment with CM-FDMSC. The downregulation of PI3K, AKT, and ERK activity may lead to cell cycle arrest and cell apoptosis. We further showed that phosphorylation of PI3K, AKT, and ERK was decreased in CM-FDMSC-treated A375 melanoma cells, compared with the control groups. Our findings are in agreement with a previous study showing that relevant MSCs inhibit Kaposi's sarcoma by a neutralizing antibody against E-cadherin through down-regulation of PI3K-AKT signaling. 37 In the research by Han, umbilical cord tissuederived MSCs were shown to inhibit tumor growth in coculture condition, via activation of JNK and downregulation of PI3K/Akt and ERK signaling. 38 Thus, our results can explain the effects of CM-FDMSC in A375 melanoma cells, such as apoptosis, migration, and invasion. Fetal MSCs are considered as the new source of MSCs with great potential, and the advantages of fetal MSCs have been well documented that they are lower immunogenicity, easier expansion in vitro, and higher proliferation potential and differentiation capability compared to adult MSCs derived from adipose. 19 Human umbilical cord blood is also a typical source of MSCs, but the successful isolating rate was much lower than bone marrow, umbilical cord, and adipose tissue. [39] [40] [41] [42] FDMSCs are relatively new players in cancer research and are showing potential for developing safe and effective clinical applications. 43 Furthermore,
FDMSCs cannot be recognized as targets by T lymphocytes in cell transplantation, and they can maintain the differentiation potential up to passage 25. 44 Moreover, owing to the histological origin, FDMSCs may have some special advantages in wound healing and skin-origin disease, and FDMSCs are considered as the main effector cells in fetal skin scarless wound healing. 45, 46 Therefore, of CM-FDMSC in A375 melanoma cells. Although we found the inhibition of PI3K/AKT and MAPK signaling may explain, at least in part, the inhibitory effects of FDMSCs on A375 melanoma cells, previous studies showed that a variety of signaling pathways were involved in A375 tumorigenicity, including Wnt/β-catenin signaling pathway, and nuclear factor-kappa B signaling pathway. 47, 48 In addition, the components in conditioned media are extremely complex, including growth factors, cytokines, extracellular vesicles, and other soluble molecules. Further investigations are required to explore the interactions between MSCs and cancer microenvironment. Also, the differences between CM of varied cells are in need of further investigation. Hence, the underlying mechanisms of CM-FDMSC antitumor effect require further investigation to isolate and characterize the active components secreted by FDMSCs and to extend our in vivo and in vitro findings to other melanoma cell lines, such as SKMel-28, WM-115, and MV3, and to primary melanomas. Ultimately, this research offers an exciting research direction with potential applications in developing novel clinical applications for treating melanoma.
Conclusion
In conclusion, our studies showed that CM-FDMSC can inhibit the tumor activity of A375 melanoma cells by suppressing the tumor formation in vivo, cell viability, migration, and invasion, and induces apoptosis of A375 melanoma cells in vitro in a dose-and time-dependent manner. The results showed that phosphorylation of PI3K, AKT, and ERK was decreased in A375 melanoma cells after different concentrations of CM-FDMSC treatment suggesting that the antitumor effects of CM-FDMSC on A375 melanoma cells may act, at least in part, through regulating PI3K/AKT and MAPK signaling pathways. Our studies highlight a promising treatment strategy for malignant melanoma.
